IFN-ε protects primary macrophages against HIV infection

JCI Insight

Volumn 1, Issue 20, 2016, Pages

  Tasker, Carley ^a   Subbian, Selvakumar ^b   Gao, Pan ^c   Couret, Jennifer ^a   Levine, Carly ^b   Ghanny, Saleena ^a   Soteropoulos, Patricia ^a   Zhao, Xilin ^a,b   Landau, Nathaniel ^d   Lu, Wuyuan ^c   Chang, Theresa L ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055605980     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.88255     Document Type: Article

References (71)

1. Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010;207(10):2053–2063.
2. Pestka S. Purification and cloning of interferon alpha. Curr Top Microbiol Immunol. 2007;316:23–37.
3. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–384.
4. González-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12(2):125–135.
5. Schoggins JW, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472(7344):481–485.
6. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87–103.
7. Cho H, Kelsall BL. The role of type I interferons in intestinal infection, homeostasis, and inflammation. Immunol Rev. 2014;260(1):145–167.
8. Teijaro JR, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340(6129):207–211.
9. Ng CT, et al. Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe. 2015;17(5):653–661.
10. Katsikis PD, Mueller YM, Villinger F. The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point? PLoS Pathog. 2011;7(8):e1002055.
11. Sandler NG, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature. 2014;511(7511):601–605.
12. Hughes R, Towers G, Noursadeghi M. Innate immune interferon responses to human immunodeficiency virus-1 infection. Rev Med Virol. 2012;22(4):257–266.
13. Oldstone MB. A Jekyll and Hyde profile: type 1 interferon signaling plays a prominent role in the initiation and maintenance of a persistent virus infection. J Infect Dis. 2015;212 Suppl 1:S31–S36.
14. Zuniga EI, Hahm B, Oldstone MB. Type I interferon during viral infections: multiple triggers for a multifunctional mediator. Curr Top Microbiol Immunol. 2007;316:337–357.
15. Doyle T, Goujon C, Malim MH. HIV-1 and interferons: who’s interfering with whom? Nat Rev Microbiol. 2015;13(7):403–413.
16. Poli G, Biswas P, Fauci AS. Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antiviral Res. 1994;24(2-3):221–233.
17. Schnittman SM, Vogel S, Baseler M, Lane HC, Davey RT. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection. J Infect Dis. 1994;169(5):981–989.
18. Sedaghat AR, et al. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol. 2008;82(4):1870–1883.
19. Sivaraman V, Zhang L, Su L. Type I interferon contributes to CD4+ T cell depletion induced by infection with HIV-1 in the human thymus. J Virol. 2011;85(17):9243–9246.
20. Sivro A, Su RC, Plummer FA, Ball TB. Interferon responses in HIV infection: from protection to disease. AIDS Rev. 2014;16(1):43–51.
21. Fung KY, et al. Interferon-ε protects the female reproductive tract from viral and bacterial infection. Science. 2013;339(6123):1088–1092.
22. Hardy MP, Owczarek CM, Jermiin LS, Ejdebäck M, Hertzog PJ. Characterization of the type I interferon locus and identification of novel genes. Genomics. 2004;84(2):331–345.
23. Xi Y, Day SL, Jackson RJ, Ranasinghe C. Role of novel type I interferon epsilon in viral infection and mucosal immunity. Mucosal Immunol. 2012;5(6):610–622.
24. Demers A, et al. The mucosal expression pattern of interferon-ε in rhesus macaques. J Leukoc Biol. 2014;96(6):1101–1107.
25. Hermant P, Francius C, Clotman F, Michiels T. IFN-ε is constitutively expressed by cells of the reproductive tract and is inefficiently secreted by fibroblasts and cell lines. PLoS One. 2013;8(8):e71320.
26. Peng FW, et al. Purification of recombinant human interferon-epsilon and oligonucleotide microarray analysis of interferon-epsilon-regulated genes. Protein Expr Purif. 2007;53(2):356–362.
27. Day SL, Ramshaw IA, Ramsay AJ, Ranasinghe C. Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy. J Immunol. 2008;180(11):7158–7166.
28. Cho HR, Kim SK, Lim HK, Jeong Park H, Chung JH, Lee MH. Association study between nonsense polymorphism (rs2039381, Gln71Stop) of interferon-ε and susceptibility to vitiligo in Korean population. Immunol Invest. 2013;42(5):423–430.
29. Kim SK, et al. T Allele of nonsense polymorphism (rs2039381, Gln71Stop) of interferon-ε is a risk factor for the development of intracerebral hemorrhage. Hum Immunol. 2014;75(1):88–90.
30. Matsumiya T, Prescott SM, Stafforini DM. IFN-epsilon mediates TNF-alpha-induced STAT1 phosphorylation and induction of retinoic acid-inducible gene-I in human cervical cancer cells. J Immunol. 2007;179(7):4542–4549.
31. Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA. Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod. 2007;13(7):491–501.
32. Abdulhaqq SA, et al. HIV-1-negative female sex workers sustain high cervical IFNε, low immune activation, and low expression of HIV-1-required host genes. Mucosal Immunol. 2016;9(4):1027–1038.
33. Keele BF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 2008;105(21):7552–7557.
34. Goujon C, et al. Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection. Retrovirology. 2013;10:23.
35. Dragin L, et al. Interferon block to HIV-1 transduction in macrophages despite SAMHD1 degradation and high deoxynucleoside triphosphates supply. Retrovirology. 2013;10:30.
36. Gramberg T, et al. Restriction of diverse retroviruses by SAMHD1. Retrovirology. 2013;10:26.
37. Hrecka K, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474(7353):658–661.
38. Goila-Gaur R, Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology. 2008;5:51.
39. Berger G, et al. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog. 2011;7(9):e1002221.
40. Goujon C, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature. 2013;502(7472):559–562.
41. Nathan C, Cunningham-Bussel A. Beyond oxidative stress: an immunologist’s guide to reactive oxygen species. Nat Rev Immunol. 2013;13(5):349–361.
42. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163–189.
43. Marchi LF, Sesti-Costa R, Ignacchiti MD, Chedraoui-Silva S, Mantovani B. In vitro activation of mouse neutrophils by recombinant human interferon-gamma: increased phagocytosis and release of reactive oxygen species and pro-inflammatory cytokines. Int Immunopharmacol. 2014;18(2):228–235.
44. West AP, et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature. 2011;472(7344):476–480.
45. West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. Nat Rev Immunol. 2011;11(6):389–402.
46. Dupré-Crochet S, Erard M, Nüβe O. ROS production in phagocytes: why, when, and where? J Leukoc Biol. 2013;94(4):657–670.
47. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82(1):47–95.
48. Kohchi C, Inagawa H, Nishizawa T, Soma G. ROS and innate immunity. Anticancer Res. 2009;29(3):817–821.
49. Ho WZ, Douglas SD. Glutathione and N-acetylcysteine suppression of human immunodeficiency virus replication in human monocyte/macrophages in vitro. AIDS Res Hum Retroviruses. 1992;8(7):1249–1253.
50. Lioy J, Ho WZ, Cutilli JR, Polin RA, Douglas SD. Thiol suppression of human immunodeficiency virus type 1 replication in primary cord blood monocyte-derived macrophages in vitro. J Clin Invest. 1993;91(2):495–498.
51. Behrendt R, et al. Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response. Cell Rep. 2013;4(4):689–696.
52. Zhang R, Bloch N, Nguyen LA, Kim B, Landau NR. SAMHD1 restricts HIV-1 replication and regulates interferon production in mouse myeloid cells. PLoS One. 2014;9(2):e89558.
53. Baca-Regen L, Heinzinger N, Stevenson M, Gendelman HE. Alpha interferon-induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes. J Virol. 1994;68(11):7559–7565.
54. Cheney KM, McKnight Á. Interferon-alpha mediates restriction of human immunodeficiency virus type-1 replication in primary human macrophages at an early stage of replication. PLoS One. 2010;5(10):e13521.
55. Goujon C, Malim MH. Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol. 2010;84(18):9254–9266.
56. Introini A, Vanpouille C, Lisco A, Grivel JC, Margolis L. Interleukin-7 facilitates HIV-1 transmission to cervico-vaginal tissue ex vivo. PLoS Pathog. 2013;9(2):e1003148.
57. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother. 2001;12(3):133–150.
58. Hansbro PM, et al. Role of NK cells in IFN-epsilon-mediated protection against female reproductive tract infection (MUC2P.925). J Immunol. 2015:194 (Supplement 1); 65.8.
59. Laguette N, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474(7353):654–657.
60. Peng G, et al. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood. 2007;110(1):393–400.
61. Chiou SH. DNA- and protein-scission activities of ascorbate in the presence of copper ion and a copper-peptide complex. J Bio-chem. 1983;94(4):1259–1267.
62. Pinti M, et al. The role of mitochondria in HIV infection and its treatment. J Exp Clin Med. 2010;2(4):145–155.
63. Kalebic T, Kinter A, Poli G, Anderson ME, Meister A, Fauci AS. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Natl Acad Sci U S A. 1991;88(3):986–990.
64. Roederer M, Staal FJ, Raju PA, Ela SW, Herzenberg LA, Herzenberg LA. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci U S A. 1990;87(12):4884–4888.
65. Peristeris P, et al. N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell Immunol. 1992;140(2):390–399.
66. Tasker C, Ding J, Schmolke M, Rivera-Medina A, García-Sastre A, Chang TL. 17β-estradiol protects primary macrophages against HIV infection through induction of interferon-alpha. Viral Immunol. 2014;27(4):140–150.
67. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185(4):621–628.
68. Chang TL, Vargas J, DelPortillo A, Klotman ME. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest. 2005;115(3):765–773.
69. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 1990;61(2):213–222.
70. Cara A, et al. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. Virology. 2002;292(1):1–5.
71. Subbian S, et al. Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits. Cell Commun Signal. 2013;11:60.